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Adult neurogenesis is attributed to the activity of progenitor cells whose 
progeny progressively mature to functional neurons under genetic and epigenetic 
influence.  
Due to the significant role of FGF6 (fibroblast growth factor 6), in the skeletal 
growth, and maintenance of progenitor cells in skeletal muscle, and the role of HDAC 
inhibitors (histone deacetylase inhibitors) in promoting neurogenesis, and increasing 
of neuronal proliferation, a combination of FGF6 with HDAC inhibitor CHDI-3 is 
investigated as a potential treatment to lessen neuronal loss in HD, by enhancing 
neurogenesis. 
Fascinatingly, FGF6 and HDAC inhibitor CHDI-3 treatment was found to be 
significantly neuroprotective in the expended huntingtin cell linesHdh111Q/111Q model 
24hours after treatment during serum withdrawal.  Results also show that FGF6 
combined with HDAC inhibitor CHDI-3 was found to activate both pERK1/2and 
BDNF pathways in the expended huntingtin cell linesHdh111Q/111Q model 1 hour after 
treatment.  
In addition, results from Morris water maze indicate that neurogenesis inhibition 
negatively regulates the learning and spatial memory, and that neurogenesis occurs 






BecausepERK1/2, and BDNF pathways activation have been implicated in 
neurogenesis, synaptic plasticity, learning, and memory and cell survival, we can 
conclude that FGF6 and HDAC inhibitors combined can be utilized for future 
therapeutic treatment to improve learning and memory for HD patients due to its 
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INTRODUCTION 
Huntington’s disease  
 
Huntington’s disease (HD) is an inherited neurodegenerative disorder with 
autosomal dominant inheritance. HD is known for characteristic choreiform 
movements. Cognitive deficits and psychiatric symptoms are frequently observed 
prior to the onset of the motor symptoms in middle age (Ranen, 1993). 
HD affects approximately 1 in 10,000 people in the U.S. (Bates, 2002). HD patients 
show atrophy of the caudate nucleus, putamen and cerebral cortex. The medium-sized 
spiny neurons in the caudate and putamen of the basal ganglia, a brain area 
responsible for coordinating movement, and the cortical layer IV and V neurons in a 
brain region, which controls thought, perception and memory, are most often 
affected(Cudkowicz and Kowall, 1990; Hedreen et al., 1991Albin, 1995).In all cases 
of HD, the disease result from a mutation in huntingtin(Htt), a ubiquitously expressed 
protein found at highest levels in neurons . The expanded CAG repeat in the Htt leads 
to polyglutamine strand of variable length at the N-terminus, which confers a toxic 
gain of protein function. The threshold for the repeat length in the disease is 36 
repeats or above.   
The mechanism by which mutant Htt causes neuronal dysfunction, is still not 
fully understood. We do know that the mutant forms of Htt are subjected to abnormal 
folding and aggregation, and may be found in intracytoplasmic or intranuclear 






In addition to the abnormal folding and aggregation of mutant Htt (mHtt), an 
increase activity of caspases, a family of proteases that are involved in apoptotic cell 
death, can also generate N-terminal fragments of Htt that can enter the nucleus and 
form nuclear inclusions in HD (Gafni et al., 2004; Hodgson JG, Agopyan N 1999). It 
has been shown that mHtt directly binds the acetyltransferase domain of CREB-
binding protein (CBP) (Steffan et al., 2001). 
There is no cure for HD, and the only available therapy is symptomatic 
treatment to help the person function for as long and as comfortable as possible 
(Bonelli and Hofman, 2007). Prior studies have shown that neurogenesis continues in 
subventricular zone (SVZ) of the lateral ventricles and subgranular zone (SGZ) of the 
hippocampal dentate gyrus (DG) in adult mouse, rat, non-human primate, and human 
brain (Chiasson et al., 1999).  Newly generated cells in the SGZ can differentiate into 
mature, functional neurons and integrate into the DG as granule cells, which are 
involved in memory formation (Kunlin Jin et al., 2005).Furthermore, an experimental 
stroke stimulates the proliferation of neuronal stem/progenitor cells located in the 
SVZ and SGZ of the adult rodent brain (Kunlin Jin et al., 2005), confirming that the 
resulting newborn cells migrate into ischemic damaged brain regions, where they 










HDAC inhibitors in Huntington disease 
A previous research confirms that Htt is subjective to the epigenetic mechanism of 
lysine acetylation and deacetylation via histone acetyltrasferases (HAT) and histone 
deacetylases (HDACs) respectively (Yang and Seto, 2007).  The inhibition of 
HDACs prevents the removal of acetyl groups, and induces transcriptional active 
gene expression. An experiment was performed with a newly developed HDAC4 
inhibitor. The results confirmed a low toxicity level in HD cells, and showed a 
therapeutic efficacy in preventing motor deficits and neurodegenerative processes in 
HD model mice (Elizabeth A. Thomas et al., 2008). A recent study indicated that an 
inhibition of HDAC synergistically promotes neurogenesis induced by a pyridoxine 
and increase of neuronal proliferation (Dae Young Yoo, et al., 2011).  In addition, 
another current study suggested that HDAC inhibitors in combination with basic FGF 
could actively drive the Embryonic Stem cells differentiate into neurons (Yao Xing, 
et al., 2010).  Overall, these results demonstrate that HDAC4 inhibitor can be of 
therapeutic benefit in HD. 
NEUROGENESIS IN ADULT BRAIN 
Adult neurogenesis is attributed to the activity of progenitor cells whose 
progeny progressively mature to functional neurons under genetic and epigenetic 






olfactory-bulb (SVZ, SGZ-OB) system, and dentate gyrus of the hippocampus 
(Federico Luzzati et al., 2007). 
A number of studies have recently demonstrated that neurogenesis is local to dentate 
gyrus.  As a result, the new granular neurons differentiate where they are generated, 
whereas neuroblast born in the rodent SVZ, undergo a long distance migration to 
olfactory bulb (Chunmei Zahao et al., 2007). 
 Ways to utilize the naturally accruing neurogenesis would involve finding 
pathways that promote cell growth, cell migration, and manipulating multiple signals 
in internal transduction pathways (Van Praag et al., 2005; Kuhn et al., 1997). The 
findings suggest that a potential treatment strategy for HD could involve the 
replacement of dead neurons by stimulating the proliferation of endogenous neuronal 
precursors, and their migration into damaged regions of the brain. This sparked a 
research on HD transgenic R6/2 mice treated by subcutaneous administration of 
fibroblast growth factor FGF-2.This research confirmed that FGF-2 improves 
neurological deficits and longevity in transgenic mouse model of HD, due to its 
neuroprotective and neuroproliferative effects (Kunlin Jin et al., 2005). 
 The Ellerby lab chose to investigate FGF6 because previous research has 
revealed the significance of FGF6 in skeletal growth in maintenance of progenitor 
cells in skeletal muscle (Armand AS et al., 2006), and in sustaining ERK 
phosphorylation(Chen, et al., 2012).  Furthermore, the potency of different FGF 
family members had never been investigated.  Comparison of all known FGF family 






HD cellular models.  This evidence directed us to test if FGF6 treatment can lessen 
neuronal loss, and enhance neurogenesis in HD transgenic zQ175 mice (Armand AS 
et al., 2006). 
Therefore our lab has formulated the following hypotheses for the use of 
neuroprotection, and neurogenesis as potential treatment to HD pathology. 
Hypothesis 1: Activation of two different neurogenesis signaling pathways, using a 
combination of FGF6, and HDAC inhibitors will increase neuronal plasticity, and 
eventually will increase learning, memory, and motor function in HD.  
Hypothesis 2: Neurogenesis depletion may have a great effect on learning, spatial 
memory, and aging.  
Hypothesis 3: Overexpression of FGF6 or with a combination of HDAC inhibitors, 
might improve the functional outcomes in zQ175 homozygous full-length knocked 













1. FGF6 and HDAC Inhibitor CHDI-3 Displayed Neuroprotection in 
Huntington’s disease Cells’ Models. 
To confirm if FGF6 and the new novel HDAC inhibitor CHDI-3 that we 
received from Cure Huntington's Disease Initiative (CHDI) were neuroprotective in 
HD, we used immortalized mouse striatal cell Hdh7Q/7Q and Hdh111Q/111Q lines to 
measure cellular toxicity. We cultured Hdh7Q/7Q and Hdh111Q/111Q cells, and measured 
the enzymes activity of caspase-3, -7, and 24 hours after these cells were plated and 
treated with FGF6, and HDAC inhibitor CHDI-3. The caspase enzyme activity was 
measured following the manufacturer’s protocol (Apo3/7 HTS, Cell Technology Inc. 
Mountain View, CA). Cell media was removed, and replaced with 25μl of 1X Apo 3 
HTS lysis buffer, and with 25μl of DMEM to each well. After gentle shaking for 5 
minutes, we removed (20μl) of the samples from the wells to measure the protein 
concentration in triplicate (BCA Protein Assay Kit, Pierce, Rockford, IL). Then we 
added 70μl of caspase 3/7 detection reagent with DTT to the remaining of 30μl of 
sample in each well (the final concentration was 1X caspase reagent and 15 mM 
DTT). A Fusion Universal Micro plate Analyzer (Perkin Elmer, Waltham, MA) was 
used to measure the fluorescence signal. 
 
Qualitatively, the measurement of cellular toxicity for FGF6 treatment at 5ng/ml 
concentration was found to be significantly neuroprotective in the expanded 
Huntington disease cell model 24 h after treatment (Figure 1A), as well as HDAC 






neuroprotective in the mouse striatal Huntington’s disease cell model after 24 hours 
of treatment, following the above protocol for the caspase assay (Figure 1B). 
Fig: 1A. Caspase activity in STHdhQ111/Q111 cells after 24 h serum withdrawal, 














Fig: 1B. Caspase activity in STHdhQ111/Q111 cells after 24 h serum withdrawal; 
show a significant reduction in caspase activity after treatment with HDAC inhibitor 
CHDI-3 
 
Neurogenesis signaling pathways 
2.Sox2, and BDNF Activation in HD 111Q cell model by FGF6 
To determine which neurogenesis signaling pathway FGF6 and HDAC 
inhibitor CHDI-3 are activating (Figure 2A), the western blot for FGF6, HDAC 
inhibitor CHDI-3, and the combination with FGF6 and HDAC inhibitor CHDI-3, 
were done according to the following protocol, and conditions; We incubated the 
mutant huntingtin striatal cells in serum withdrawal media for 3 hours, next we 
treated the cells with 5ng/ml of FGF6 for one hour, then we lysed the cells using lysis 






measured protein concentrations using BCA Protein Assay Kit.  We loaded 20μg of 
each sample per well on a NuPage 4–12% Bis-Tris gel (Invitrogen Corporation, 
Carlsbad, CA), next we ran all the samples on the same gel at the same time. We 
transfer over night at 4oC, blocked with milk for one hour, and then we probed the 
blot with the following antibodies Sox2, BDNF, and beta tubulin for overnight. After 
that we washed the blot, and we probed the blots with the secondary for one hour, and 
then put the blot on the same film to avoid the exposure time differences. 
Finally to quantify the level of Sox2 and BDNF, we used Image-Quant software to 
measure the volumetric of the Sox2 and BDNF bands. 
Fig: 2A. Neurogenesis signaling pathways 
  
Our quantitative analysis software demonstrated that 5ng/ml concentration of FGF6 
increased significantly the expression level of BDNF in the mutant HdhQ111striatal 
cells, and showed a trend of increase for the level of Sox2.  This suggests that FGF6 
enhances significantly neurogenesis and plasticity signaling pathway, through the 







3.FGF6 mediated pERK1/2 in the mutant HdhQ111striatal cells 
To demonstrate if FGF6 activates pERK /ERK the upstream of Sox2, we incubated 
mutant HdhQ111 striatal cells in serum withdrawal for 3 hours, then treated with 
5ng/ml FGF6 for one hour, after that we followed the above lab protocol for the 
western blot, but using this time the primary antibody for pERK, primary antibody for 
ERK, and b-tubulin, to measure the levels of pERK /ERK using Image-Quant 
software. 
The quantitative analysis result shows that the mutant Huntington’s disease striatal 
cells treated with 5ng/ml of FGF6 exhibited an increase for pERK44/ERK comparing 
to untreated Hdh111Q/111Qcells, and wild type striatal cells, suggesting that FGF6 
enhances neurogenesis-signaling pathway through the activation of pERK/ERK 
pathway (Figure 3A). 
Fig: 2B. Immunoblot and its quantification show an increase in Sox2, and BDNF in 








Fig: 3A. Immunoblot show increase in ERK phosphorylation in STHdhQ111/Q111 
cells after one-hour treatment with FGF6 in SFM, followed by Quantification of the 
phospho-ERK/ß-tubulin ratio for p44 (ERK1) and p42 (ERK2) bands. 
  
4. FGF6 with HDAC inhibitor CHDI-3 mediated BDNF activation in HD 111Q 
cell model 
We examined the effect of the combination of HDAC inhibitor CHDI-3 with FGF6 
on BDNF expression level in mutant Hdh111Q/111Q striatal cells, by incubating the 
mutant Hdh111Q/111Q striatal cells in serum withdrawal for 3 hours, then treated the 
cells with 0.5uM HDAC inhibitor CHDI-3 combined with 2.5ng/ml FGF6 for 1 hour, 
using the same western blot lab protocol, and the quantitative analysis mentioned 
above.  The results confirmed that mutant huntingtin striatal cells treated with 
2.5ng/ml of FGF6 combined with 0.5 uM of HDAC inhibitor CHDI-3, exhibited a 







5. FGF6 with HDAC inhibitor CHDI-3 mediated pERK1/2 activation in 
Hdh111Q/111Q cell model 
 In addition to BDNF, we measure the effect of HDAC inhibitor CHDI-3 and FGF6 
on pERK1/2 by incubating mutant Huntington striatal cells in serum withdrawal for 3 
hours, then treated them with 2.5ng/ml of FGF6 combined with 0.5 uM of HDAC 
inhibitor CHDI-3, using the same condition used above. The result showed a 
significant increase in ERK1/2 phosphorylation (figure 5A), comparing to mutant 
Huntington’s disease striatal cells in the serum withdrawal.  
6. pCREB/CREB increase in Hdh111Q/111Qcell model by FGF6 and HDAC 
inhibitor CHDI-3 
To confirm if pCREB/ CREB is effected by HDAC inhibitor CHDI-3 combined with 
FGF6, the mutant huntingtin striatal cells were incubated in serum withdrawal for 3 
hours, then treated with 2.5ng/ml of FGF6 combined with 0.5 uM of HDAC inhibitor 
CHDI-3, for one hour, and using the above western blot protocol, and the quantitative 
analysis software. The quantification of pCREB/CREB level in the mutant 
Huntington striatal cells treated with HDAC inhibitor CHDI-3 with FGF6 showed a 
trend of increase compared to mutant Huntington striatal cells in the serum 











Fig: 4A. Immunoblot and its quantification show an increase of BDNF in 
STHdhQ111/Q111 cells after 1hour treatment with FGF6 combined with HDAC 
inhibitor CHDI-3 in SFM 
 
Fig: 5A. Immunoblot show increase in ERK phosphorylation in STHdhQ111/Q111 
cells after one-hour treatment with FGF6 combined with HDAC inhibitor CHDI-3 in 
SFM, followed by Quantification of the phospho-ERK/ß-tubulin ratio for p44 (ERK1) 







Fig: 6A. Immunoblot and its quantification, show an increase in CREB/ß -tubulin, 
and phospho-CREB/ß-tubulin ration in STHdhQ111/Q111 cells, after one-hour 
treatment with FGF6 combined with HDAC inhibitor CHDI-3 in SFM. 
  
7.Morris Water Maze (MWM) Test 
Conditional inhibition of Neurogenesis/ Immunohistochemistry:  
To ensure that the inhibition of neurogenesis occurred for our transgenic TK-DCX 
mice, treated with anti-viral gancyclovir drug (GCV) for 14 days, the sections of the 
brains presenting Subventricular zone SVZ of Tg/saline, Tg/GCV, WT/Saline, and 
WT/ GCV groups were embedded in PFA %4, 7.4 pH, and cut to 7um slides, so we 
can be able to use immunohistochemistry on the slides.  We used immunofluorescent 
staining of double cortin (DCX) with BrdU. The confocal imaging taken by our lab, 






transgenic TK-DCX, treated with GCV drug, comparing to the wild type mice brain 
treated with GCV, and Saline (Figure 7A). 
Fig: 7.A. Confocal images of ablation of adult cells population in mouse Tg-TK-
DCX, GCV, and Wild type saline (K Zafar, 2013). 
 
Neurogenesis inhibition negatively effect learning, spatial memory, and aging 
To determine whether learning, and spatial memory requires neurogenesis in young 
and old mice, we tested learning and spatial memory on five months old, and one year 
old wild type, and Tg-TK-DCX mice treated with GCV, by an intra-IP injection of 
Gancyclovir GCV (2.5mg/ml), and saline for 14 days. Saline was used as a vehicle, 
prior to injection. (N=12 mice used for each group). 
Latency to reach the platform (sec) for 5 months–old DCX mice (learning test) 
 Morris Water Maze data Analysis demonstrated that the control mice; GCV treated 
wild type mice group, Saline treated wild type mice group, and Saline treated 
transgenic mice group, performed better than treated transgenic mice with GCV for 






that treated transgenic mice showed a significant decline in latency time to find the 
platform comparing to control mice, concluding that there is a decline of learning in 
treated transgenic mice comparing to the controls (Figure 7B).  
Frequency to platform zone for five months old DCX mice (memory test) 
Morris Water Maze memory test showed that treated transgenic mice spent 
significantly less time in the target quadrant for the probe (hidden platform), 
comparing to the control mice, which spent significantly more time in the target 
quadrant (Figure 7C). 
Fig: 7. B. Latency to reach the platform (sec) for 5 months–old DCX mice (learning 
test), C. Frequency to platform zone for five months old DCX mice (memory test). 
B.                                                                       C. 
 
Latency to reach platform (sec) for one-year-old DCX mice (learning test) The 






latency time to find the platform, between the controls and the treated transgenic mice 
with GCV, concluding that neurogenesis inhibition had no major effect on learning in 
the aging mice, like it did for the younger transgenic DCX-TK mice (Figure 7D).   
Frequency to platform zone for one-year-old DCX mice (memory test) 
The spatial memory test data analysis, showed no significant difference for the time 
spent in the target quadrant between the control mice and the treated transgenic mice 
with GCV, concluding that neurogenesis inhibition had no major effect on memory in 
the aging mice like it did for the younger transgenic DCX-TK mice. (Figure 7E). 
Fig: 7. D. Latency to reach platform (sec) for one-year-old DCX mice (learning test), 
E. Frequency to platform zone for one-year-old DCX mice (memory test) 











The caspase-3/7 assay confirmed that the growth factor FGF6 and HDAC 
inhibitor CHDI-3 are significantly neuroprotective in the Huntington’s disease cell 
model 24 hours after treatment during serum withdrawal 
 In addition, the western blot results revealed that FGF6 alone, or with the 
combination of HDAC inhibitor CHDI-3 could enhance two different neurogenesis-
signaling pathways, through the activation of pERK1/2 pathway, and the activation of 
BDNF pathway.  The ability to activate two different neurogenesis-signaling 
pathways, will eventually lead to a significant increase in learning and memory.  
Furthermore, the Morris water maze results indicates that the inhibition of 
neurogenesis contribute to a deficits in the learning and spatial memory in five 
months old DCX –TK mice treated with GCV, comparing to the control mice.  
On the contrary, the inhibition of neurogenesis in the one-year-old mice 
showed no significant difference in learning and spatial memory between the control 
mice, and the transgenic DCX –TK mice treated with GCV. These results clearly 
confirm to us the involvement and the importance of neurogenesis in influencing 
learning and spatial memory, and revealed to us that neurogenesis occurs more in the 









In conclusion, our study confirmed the involvement and the importance of 
neurogenesis in influencing learning and spatial memory, and demonstrated that a 
combination of FGF6 with HDAC inhibitor CHDI-3, have the ability to enhance two 
different neurogenesis signaling pathways, through the activation of pERK1/2 and the 
activation of BDNF, leading to an increase in learning and memory.   These results 
suggest that FGF6 combined with HDAC inhibitor CHDI-3, can be utilized for future 


































RESEARCH DESIGN AND METHODS 
 
Induce Neurogenesis in Huntington’s disease  
Cell culture 
The striatal cell lines (Hdh7Q/7Q  and  Hdh111Q/111Q) were used in this study. 
Hdh7Q/7Q  and  Hdh111Q/111Q  cells  were  generously  provided  by  Dr.  Marcy  MacDo
nald. The striatal cell lines were maintained at 33°C in a humidified atmosphere of 
95% air and 5% CO2, in Dulbecco's modified eagle medium (DMEM; Cellgro) 
supplemented with 10% FBS, 100 U/mL penicillin and 100 g/mL streptomycin. 
Cells were fed with fresh medium every 2–3 days. The PC12 cell lines (23Q and 
103Q), kindly supplied by Dr E. S. Schweitzer, were maintained at 37°C in a 
humidified atmosphere of 90.5% air and 9.5% CO2, in Dulbecco's modified eagle 
medium (DMEM; Cellgro) supplemented with 10% heat inactivated horse serum, 5% 
FBS and 100 U/mL penicillin and 100 g/mL streptomycin on collagen coated plates 
and fed every 2-3 days. PC12 cells are inducible cell lines in which mhtt were 
induced by tebufenozide (1uM). 
Caspase 3/7 Assay  
Caspase 3/7 activities was measured by using kit as per manufacturer’s direction 
(Mountain View, CA) and normalized by protein concentration expressed 
as  caspase  3/7   activity  in  RFU/min/mg  protein. Briefly, cells were lysed in 
working cell lysis buffer (50uL, 1:1 lysis buffer: serum free DMEM), cell were lysed 






measure protein. Afterwards 70 uL of working lysis buffer with DTT (20mM), and 
2% caspase substrate Rhodamine-DEVD   conjugate   (zDEVD) 2-Rhodamine   
110)  added to remaining lysed cells, shake briefly and then read at 37C for 50 reads 
on Fusion-Alpha FP HT flourometer (Perkin Elmer) at Ex485nm/Em530nm.  
Western blot analysis 
Cells were harvested in M-PER buffer (Thermo Scientigic) containing a cocktail of 
protease (Roche) and phosphatase inhibitors (Calbiochem).  Cells were lysed by 
sonication at 30mA for 3x3 sec. Protein concentration was determined using the BCA 
kit 
(Thermo Scientific) following the manufacturer’s instructions of protein containing 
1x LDS buffer and 100mM DTT is incubated at 950C for 10 min to induce protein 
denaturation. Following incubation on ice for 2 min, 20µg protein samples were 
resolved under reducing conditions in MES Buffer (Invitrogen) on precast 4-12% 
NuPage gels at 200V for 1hr. Proteins are transferred to 40µm nitrocellulose 
membranes in transfer buffer at a constant 20V for 14hrs at 40C. Membranes were 
blocked in 3% non-fat milk in TBST for 1hr at room temperature. For phospho-
specific antibodies, 3% BSA in TBST was used to block the membranes. Western 
blots were probed overnight at 40C with primary antibody anti-rabbit phospho ERK 
(1:1000, Cell Signaling, #4370), anti-rabbit ERK (1:1000, Cell Signaling, #4695), 
anti-rabbit phospho CREB (1:1000, Cell Signaling, #9191), anti-mouse CREB 
(1:1000, Cell Signaling, #9104), anti-rabbit BDNF (1:1000, Santa Cruz, sc-546), anti-






incubated with HRP coupled secondary antibodies (1:3000) for 1 hr and 
immunoreactivity bands were visualized using the Pierce ECL kit (Thermo Scientific) 
and Hyperfilm (Kodak). 
Adenovirus construction 
Standard cloning techniques were used to construct all recombinant AAV-based 
plasmids. Recombinant expression plasmids containing, the human FGF6 cDNA 
clone that’s been bought through ABGENT, using Invitrogen pcDNA, 4.0 to myc his 
A, Vector.  
The Shuttle vector G0345/ pFBAAVCAGmcsBgHpA, and the control AAV with a 
GFP, were bought from the Gene Transfer Vector Core of University of IOWA, 
Carver College of Medicine.  
The pFBAAVCAGFGF6 plasmid was constructed by a subcloning protocol. The 
CAG promoter region from pAAVCAG amplified by polymerase chain reaction 
(PCR), using the primers FGF6  
–Sal1_Fwd-5′-(GCATGTCGACATGGCCCTGGGACAGAAACT)-3′, FGF6_Mlu1_ 
Rev-5′-(GATCACGCGTTAGAAGGCACAGTCGGAGG)-3′, and BGH_Rev-5′-
(TAGAAGGCACAGTCGAGG)-3′, which contain Sal1, Mlu1 and BamHI restriction 
sites, respectively (underlined). This FGF6 insert in the pFBAAVCAG was then sent 
to the Gene Transfer Vector Core at University of IOWA, Carven College of 










Experimental design and stereotaxic injection 
 
Q175z Homo mice, were injected with AAVCAGFGF6 Adeno Associate 
virus with a CAG promoter with an insert of FGF6, and injected with the control 
vector AAVGFP, using stereotaxic and a Hamilton syringe into the both striatum area 
of the Q175z mouse brain.  Each side was injected by 2μl of the virus (−2.5 mm 
anterior to bregma, 3 mm lateral to midline, and 2 mm beneath the dura). 
Experimental protocols were in accordance with the National Institutes of Health 
Guidelines for Use of Live Animals and were approved by the Animal Care and Use 
Committee at the Buck Institute. All possible efforts were made to minimize the 
number of animals used and their suffering. 
Immunohistochemistry 
Mice used in our Morris water maze were transcardially perfused with 4% 
paraformaldehyde and brains were paraffin-embedded, sectioned and deparaffinized 
with xylene. After antigen retrieval, sections were processed for 
immunohistochemical localization of DCX double cortin using anti-rabbit DCX 
(1:50, Santa Cruz, #8607), anti mouse BrdU (1:100, Roche,  #1-299-964).   
The primary antibodies diluted in 1% BSA overnight. Prior to primary antibody 
incubation samples were blocked in 10% Donkey serum in TBS. To remove non-
specific binding, samples were washed 3 × in TBS (10min). Antigens were 
visualized with Alexa Fluor secondary antibodies (1:500).  
Tissues were labeled for Brdu and DCX as described previously (Jin et al., 2005). 






(Benraiss et al., 2001;Nunes et al., 2003); (Ivkovic and Ehrlich, 1999) 
Animals. 
We produced transgenic mice that express herpes simplex virus thymidine 
kinase (TK) under control of the promoter for doublecortin (Dcx), a microtubule-
associated protein expressed in newborn and migrating neurons. Treatment for 14 
days with the antiviral drug gancyclovir (GCV) depleted Dcx-expressing and BrdU-
labeled cells from the rostral subventricular zone, and abolished neurogenesis.   
Identification and characterization of transgenic mouse lines was performed by PCR 
using HSV-TK-specific primers (HSVTK-1: 5′-CCACCACG CAACTGCTGGTG-3′; 
and HSVTK-2: 5′-CGAGG CGGTGTTGTGTGGTGT-3′). Mice were used in 
experiments at age 5 to 12 months. Mice were group-housed in an enriched 
environment with igloo tunnels and unlimited access to food and water. Cages were 
also equipped with wood shavings, cotton nestlets and a filter top. Temperature, 
humidity and a 12 h light/dark cycle were tightly controlled. All experimental 
procedures were conducted in accordance with the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals to minimize animal suffering and 
number for the present study.  
Morris water Maze 
 Many neurodegenerative disease mouse models (including polyQ expansion) 
display learning deficits (Chen et al.,Nature (2000) 408, 975-9).  Learning and memory 






and 12 months of age with a Morris water maze in experiments similar to those 
described (Palop et al., Proc NatlAcadSci U S A (2003) 100:9572). The ability of 
experimental animals to locate a visible platform in a pool filled with opaque water 
was tested to exclude differences in vision and swim speed. Animals were trained for 
5 days, in 2 sessions, 2.5 hours apart. Each session consisted of 3 consecutive trials. 
The platform location stayed constant for each mouse, while the starting point at 
which the mouse will be placed into the water was changed for each trial. Spatial 
learning was measured as decreases in the time elapsed until each animal reached the 
hidden platform and as decreases in path length. On days 5 and 7, probe trials in 
which the platform has been removed was performed, and the time each animal 
spends in the quadrant where the platform was previously located or frequency of 
crossing platform zone was recorded as a measure of memory retention. In either case, 
mice were carefully observed for signs of distress during the test.  Any mouse in distress 
was immediately removed from the water maze. 
Rotarod 
 
Animals were tested on a Rotamex Rotarod (Columbus Instruments) on three 
consecutive days during the dark phase of the 12 h dark cycle. The tests were 
performed three trials each day, with breaks of at least 1 h between tests. In each trial, 
mice were placed in separate chambers on the resting rod before rotation was 
initiated. After 5 seconds of constant slow rotation the speed was increased gradually 
over the course of 5 minutes from 4 to 40 r.p.m. The timer was stopped either 






cases when the mouse gripped the rod and started rotating with it.  This landing area 
and this process did not injure the mice. 
 
All experiments and animal care were performed in accordance with the Buck 
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